Drug Type Small molecule drug |
Synonyms DWP 212525, DWP-212525, DWP212525 |
Target |
Mechanism BTK inhibitors(Tyrosine-protein kinase BTK inhibitors), JAK3 inhibitors(Tyrosine-protein kinase JAK3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Phase 1 | KR | 10 Dec 2024 | |
COVID-19 | Preclinical | KR | - | |
Inflammatory Bowel Diseases | Preclinical | KR | - | |
Pemphigus | Preclinical | KR | - | |
Rheumatoid Arthritis | Preclinical | KR | - | |
Systemic Lupus Erythematosus | Preclinical | KR | - |